Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
NIPS Boosts Overall Survival Over PS in Gastric Cancer With Peritoneal Metastasis
January 24th 2025, 10:10pm
Gastrointestinal Cancers Symposium (ASCO GI)
Intraperitoneal and intravenous paclitaxel plus S-1 improved OS over intravenous paclitaxel and S-1 alone in gastric cancer with peritoneal metastasis.
Pamrevlumab Plus Chemo Fails to Improve Survival in Unresectable Locally Advanced Pancreatic Cancer
January 24th 2025, 9:29pm
Gastrointestinal Cancers Symposium (ASCO GI)
Pamrevlumab plus chemotherapy failed to demonstrate a survival benefit in patients with locally advanced, unresectable pancreatic cancer.
Dr Spira on RMC-9805 in KRAS G12D–Mutated Pancreatic Ductal Adenocarcinoma
January 24th 2025, 9:25pm
Gastrointestinal Cancers Symposium (ASCO GI)
Alexander I. Spira MD, PhD, FACP, FASCO, discusses data of RMC-9805 in previously treated, advanced KRAS G12D–mutated pancreatic ductal adenocarcinoma.
Surufatinib Plus TAS-102 Displays Activity, Safety in Later-Line Metastatic PDAC
January 24th 2025, 8:36pm
Gastrointestinal Cancers Symposium (ASCO GI)
Surufatinib with TAS-102 produced promising survival outcomes and manageable toxicity as later-line therapy for a small cohort of patients with PDAC.
Frontline Nivolumab/Ipilimumab Prolongs OS in Unresectable HCC
January 24th 2025, 8:35pm
Gastrointestinal Cancers Symposium (ASCO GI)
Nivolumab plus ipilimumab produced a statistically significant and clinically meaningful OS benefit vs SOC in systemic therapy–naive unresectable HCC.
RAS(ON) Inhibitor Zoldonrasib Is Safe, Shows Early Activity Signals in KRAS G12D–Mutated PDAC
January 24th 2025, 8:14pm
Gastrointestinal Cancers Symposium (ASCO GI)
Zoldonrasib was well tolerated and associated with manageable AEs and preliminary antitumor activity in patients with KRAS G12D–mutated PDAC.
Addition of Camrelizumab and Rivoceranib to TACE Boosts PFS in Unresectable HCC
January 24th 2025, 7:46pm
Gastrointestinal Cancers Symposium (ASCO GI)
TACE with camrelizumab and rivoceranib elicited a clinically meaningful PFS improvement among patients with unresectable HCC.
Cabozantinib Bests Placebo in Extrapancreatic NETs With Primary Tumor Arising in the Gl Tract
January 24th 2025, 6:55pm
Gastrointestinal Cancers Symposium (ASCO GI)
A subgroup analysis of the CABINET trial showed that cabozantinib extended PFS vs placebo in extrapancreatic NETs with a primary tumor arising in the GI tract.
Neoadjuvant Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC
January 24th 2025, 5:50pm
Gastrointestinal Cancers Symposium (ASCO GI)
Neoadjuvant sintilimab plus chemoradiotherapy improved pCR rates in resectable, locally advanced esophageal squamous cell carcinoma.
Dr Goel on the Future of an Exosome-Based Liquid Biopsy Plus the Biomarker CA19-9 to Detect Early-Stage Pancreatic Cancer
January 24th 2025, 5:31pm
Gastrointestinal Cancers Symposium (ASCO GI)
Ajay Goel, PhD, AGAF, discusses upcoming clinical studies examining the prognostic biomarker CA19-9 plus an investigational exosome-based liquid biopsy for the detection of early-stage pancreatic cancer.
Trastuzumab/Pertuzumab/Chemo Does Not Confer Response Advantage in Gastric/GEJ Cancer
January 24th 2025, 1:25am
Gastrointestinal Cancers Symposium (ASCO GI)
Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.
Tislelizumab Plus Chemotherapy Is Active, Tolerable in Advanced Gastric/GEJ Cancer
January 24th 2025, 12:57am
Gastrointestinal Cancers Symposium (ASCO GI)
Tislelizumab plus irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin showcased encouraging efficacy and manageable safety in gastric/GEJ cancer.
First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer
January 23rd 2025, 9:10pm
Gastrointestinal Cancers Symposium (ASCO GI)
Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.
Evorpacept Plus TRP Generates Superior Antitumor Responses, Survival Outcomes in HER2+ Gastric/GEJ Cancer
January 23rd 2025, 8:56pm
Evorpacept plus TRP produced superior ORR, DOR, and PFS outcomes vs TRP alone in patients with HER2-positive gastric or gastroesophageal junction cancer.
First-Line Tislelizumab Plus Chemo Elicits Deep Responses Linked to OS Benefits in ESCC
January 23rd 2025, 7:30pm
Gastrointestinal Cancers Symposium (ASCO GI)
OS benefits with tislelizumab plus chemotherapy were comparable between early and late responders in the phase 3 RATIONALE-306 study in patients with ESCC.
Nivolumab Plus Chemo Shows Long-Term OS Benefit in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer
January 23rd 2025, 7:30pm
Gastrointestinal Cancers Symposium (ASCO GI)
Nivolumab plus chemotherapy demonstrated long-term survival benefits in advanced gastric, GEJ, or esophageal cancer in China.
Oncology Experts Preview Top Abstracts to be Shared at 2025 ASCO GI
January 22nd 2025, 11:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
Tanios S. Bekaii-Saab, MD, and Yelena Y. Janjigian, MD, preview top presentations from this year’s Gastrointestinal Cancers Symposium.
Everolimus Plus Lanreotide Extends PFS in Advanced GEP-NETs
January 21st 2025, 10:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
Everolimus plus lanreotide demonstrated an improved PFS compared with everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
Nivolumab Plus Gemcitabine/Cisplatin Shows Favorable OS/PFS Trend in Asian Unresectable/Metastatic Urothelial Cancer Subpopulation
January 15th 2025, 3:06pm
First-line nivolumab plus chemotherapy numerically improved survival vs chemotherapy alone in Asian patients with unresectable/metastatic urothelial cancer.
Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC
January 9th 2025, 1:00pm
Durvalumab plus vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in BCG-unresponsive NMIBC.